Lu Wang

List of Publications by Year
in descending order

90 papers	9,638 citations	66343 42 h-index	46799 89 g-index
91 all docs	91 docs citations	91 times ranked	13762 citing authors

#	Article	IF	Citations
1	Genomic profiling identifies genes and pathways dysregulated by HEY1â€“NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis. Journal of Pathology, 2022, 257, 579-592.	4.5	7
2	RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data. Leukemia, 2022, 36, 1492-1498.	7.2	16
3	Lipoblastomas presenting in older children and adults: analysis of 22 cases with identification of novel PLAG1 fusion partners. Modern Pathology, 2021, 34, 584-591.	5.5	29
4	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. Modern Pathology, 2021, , .	5.5	3
5	Sclerosing epithelioid mesenchymal neoplasm of the pancreasÂâ€“Âa proposed new entity. Modern Pathology, 2020, 33, 456-467.	5.5	10
6	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
7	Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma. Human Pathology, 2020, 104, 73-83.	2.0	5
8	Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. Blood Advances, 2020, 4, 2991-2995.	5.2	10
9	Infratentorial C11orf95-fused gliomas share histologic, immunophenotypic, and molecular characteristics of supratentorial RELA-fused ependymoma. Acta Neuropathologica, 2020, 140, 963-965.	7.7	14
10	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. International Journal of Molecular Sciences, 2019, 20, 3939.	4.1	27
11	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	2.0	38
12	Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Modern Pathology, 2019, 32, 609-620.	5.5	112
13	Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. American Journal of Surgical Pathology, 2018, 42, 767-777.	3.7	33
14	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Modern Pathology, 2018, 31, 881-889.	5.5	8
15	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of Oncology, 2018, 29, 1394-1401.	1.2	72
16	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer, 2018, 17, 71-77.	1.9	10
17	Sinonasal Secretory Carcinoma of Salivary Gland with High Grade Transformation: A Case Report of this Under-Recognized Diagnostic Entity with Prognostic and Therapeutic Implications. Head and Neck Pathology, 2018, 12, 274-278.	2.6	21
18	A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms. Modern Pathology, 2018, 31, 132-140.	5.5	17

#	Article	IF	Citations
19	Atypical lipomatous tumor of the hand with transformation to dedifferentiated liposarcoma: a case report. Skeletal Radiology, 2018, 47, 703-709.	2.0	0
20	TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid. Leukemia Research, 2018, 74, 51-54.	0.8	13
21	Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genetics, 2018, 228-229, 236-250.	0.4	26
22	Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms. Modern Pathology, 2018, 31, 1733-1743.	5.5	40
23	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6030-E6038.	7.1	44
24	A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia. Leukemia Research Reports, 2017, 7, 17-19.	0.4	7
25	Generation of conditional oncogenic chromosomal translocations using <scp>CRISPR</scp>â€“Cas9 genomic editing and homologyâ€directed repair. Journal of Pathology, 2017, 242, 102-112.	4.5	23
26	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
27	YWHAE -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic Oncology, 2017, 145, 531-535.	1.4	32
28	Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms. Journal of Molecular Diagnostics, 2017, 19, 387-396.	2.8	36
29	Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22). American Journal of Dermatopathology, 2017, 39, 304-309.	0.6	10
30	BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Modern Pathology, 2017, 30, 1251-1261.	5.5	112
31	Genetic Heterogeneity in Therapy-NaÃ¯ve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research, 2017, 23, 4402-4415.	7.0	91
32	Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma. Human Pathology, 2017, 70, 113-120.	2.0	16
33	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
34	Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. International Journal of Gynecological Pathology, 2017, 36, 76-89.	1.4	26
35	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood, 2017, 130, 1644-1648.	1.4	82
36	Chromosomal abnormalities of highâ€grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology, 2017, 71, 719-724.	2.9	20

#	Article	IF	Citations
37	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight, 2017, 2, .	5.0	89
38	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
39	Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. Journal of Pediatric Hematology/Oncology, 2016, 38, e166-e168.	0.6	3
40	Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes Chromosomes and Cancer, 2016, 55, 591-600.	2.8	58
41	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of Oncology, 2016, 27, 1286-1291.	1.2	92
42	What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Annals of Oncology, 2016, 27, 920-926.	1.2	261
43	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
44	Symplastic/pseudoanaplastic giant cell tumor of the bone. Skeletal Radiology, 2016, 45, 929-935.	2.0	25
45	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305.	5.5	68
46	The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study. Journal of Pathology: Clinical Research, 2016, 2, 9-20.	3.0	24
47	A proportion of primary squamous cell carcinomas of the parotid gland harbour highâ€risk human papillomavirus. Histopathology, 2016, 69, 921-929.	2.9	15
48	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	10.7	365
49	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	12.8	140
50	Atypical Renal Cysts. American Journal of Surgical Pathology, 2016, 40, 202-211.	3.7	17
51	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6â€"NTRK3 fusion. Modern Pathology, 2016, 29, 985-995.	5.5	74
52	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
53	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical Cancer Research, 2016, 22, 2351-2358.	7.0	141
54	Consistent copy number changes and recurrent <scp>PRKAR1A</scp> mutations distinguish <scp>M</scp>elanotic <scp>S</scp>chwannomas from <scp>M</scp>elanomas: <scp>SNP</scp>â€array and next generation sequencing analysis. Genes Chromosomes and Cancer, 2015, 54, 463-471.	2.8	44

#	Article	IF	Citations
55	Vulvar Myxoid Liposarcoma and Well Differentiated Liposarcoma With Molecular Cytogenetic Confirmation. International Journal of Gynecological Pathology, 2015, 34, 390-395.	1.4	12
56	TFE3 Translocationâ€“associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. American Journal of Surgical Pathology, 2015, 39, 394-404.	3.7	140
57	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true â€œoligoastrocytomaâ€?. Acta Neuropathologica, 2015, 129, 151-153.	7.7	87
58	Broad, Hybrid Captureâ€“Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research, 2015, 21, 3631-3639.	7.0	236
59	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Annals of Oncology, 2015, 26, 1704-1709.	1.2	18
60	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discovery, 2015, 5, 610-621.	9.4	129
61	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
62	Optimizing the Sequence of Anti-EGFRâ€“Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 542-552.	4.1	28
63	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
64	Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature, 2014, 514, 385-388.	27.8	187
65	Rationale for co-targeting IGF-1R and ALK in ALK fusionâ€“positive lung cancer. Nature Medicine, 2014, 20, 1027-1034.	30.7	243
66	SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Letters, 2014, 351, 143-150.	7.2	13
67	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. Journal of Thoracic Oncology, 2014, 9, 892-896.	1.1	106
68	A Genome-Wide High-Resolution Array-CGH Analysis of Cutaneous Melanoma and Comparison of Array-CGH to FISH in Diagnostic Evaluation. Journal of Molecular Diagnostics, 2013, 15, 581-591.	2.8	71
69	Identification of cancer gene fusions based on advanced analysis of the human genome or transcriptome. Frontiers of Medicine, 2013, 7, 280-289.	3.4	6
70	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern Pathology, 2013, 26, 511-522.	5.5	95
71	Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas. Cancer Discovery, 2013, 3, 630-635.	9.4	438
72	Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita. International Journal of Surgical Pathology, 2013, 21, 520-525.	0.8	9

#	Article	IF	Citations
73	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research, 2012, 18, 6599-6608.	7.0	169
74	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
75	Identification of a novel, recurrent HEY1â€NCOA2 fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
76	Multiplex testing for driver mutations in squamous cell carcinomas of the lung.. Journal of Clinical Oncology, 2012, 30, 7505-7505.	1.6	21
77	The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics, 2011, 43, 668-672.	21.4	617
78	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	12.4	457
79	Inhibition of Aberrant Androgen Receptor Induction of Prostate Specific Antigen Gene Expression, Cell Proliferation and Tumor Growth by 17Î±-Estradiol in Prostate Cancer. Journal of Urology, 2011, 185, 305-314.	0.4	10
80	PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes and Development, 2010, 24, 2205-2218.	5.9	181
81	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009, 28, 2773-2783.	5.9	205
82	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	7.1	1,557
83	Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions. Journal of Molecular Diagnostics, 2007, 9, 498-509.	2.8	142
84	Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma. BMC Cancer, 2007, 7, 172.	2.6	50
85	Hornerin gene was involved in a case of acute myeloid leukemia transformed from myelodysplastic syndrome with t(1;2)(q21;q37). Leukemia, 2006, 20, 2184-2187.	7.2	6
86	Cathepsin K in Adipocyte Differentiation and Its Potential Role in the Pathogenesis of Obesity. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4520-4527.	3.6	55
87	Receptor Isoform and Ligand-Specific Modulation of Dihydrotestosterone-Induced Prostate Specific Antigen Gene Expression and Prostate Tumor Cell Growth by Estrogens. Journal of Andrology, 2005, 26, 500-508.	2.0	23
88	A decade?s studies on metastasis of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2004, 130, 187-196.	2.5	406
89	Environment, genome and cancer. Comptes Rendus De L'AcadÃ©mie Des Sciences SÃ©rie 3, Sciences De La Vie, 2001, 324, 1085-1091.	0.8	4
90	Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes and Cancer, 2001, 31, 221-227.	2.8	64